CORTICAL SEROTONIN-S2 RECEPTOR-BINDING IN LEWY BODY DEMENTIA, ALZHEIMERS AND PARKINSONS DISEASES

被引:88
|
作者
CHENG, AVT
FERRIER, IN
MORRIS, CM
JABEEN, S
SAHGAL, A
MCKEITH, IG
EDWARDSON, JA
PERRY, RH
PERRY, EK
机构
[1] NEWCASTLE GEN HOSP,DEPT NEUROPATHOL,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND
[2] NEWCASTLE GEN HOSP,BRIGHTON CLIN,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND
[3] ROYAL VICTORIA INFIRM,DEPT PSYCHIAT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND
关键词
SEROTONIN; SEROTONIN RECEPTOR; SENILE DEMENTIA OF LEWY BODY TYPE; ALZHEIMERS DISEASE; PARKINSONS DISEASE; KETANSERIN;
D O I
10.1016/0022-510X(91)90193-B
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The binding of the selective 5-HT2 antagonist [H-3]ketanserin has been investigated in the temporal cortex of patients with Alzheimer's disease (SDAT), Parkinson's disease (PD), senile dementia of Lewy body type (SDLT) and neuropathologically normal subjects (control). 5-HT2 binding was reduced in SDAT, PD with dementia and SDLT. SDAT showed a 5-HT2 receptor deficit across most of the cortical layers. A significant decrease in 5-HT2 binding in the deep cortical layers was found in those SDLT cases without hallucinations. SDLT cases with hallucinations only showed a deficit in one upper layer. There was a significant difference in cortical layers III and V between SDLT without hallucinations and SDLT with hallucinations. The results confirm an abnormality of serotonin binding in various forms of dementia and suggest that preservation of 5-HT2 receptor in the temporal cortex may differentiate hallucinating from non-hallucinating cases of SDLT.
引用
收藏
页码:50 / 55
页数:6
相关论文
共 50 条
  • [31] LACK OF EFFECT OF RAPHE LESIONS ON SEROTONIN-S2 RECEPTOR CHANGES INDUCED BY AMITRIPTYLINE AND DESMETHYLIMIPRAMINE
    DUMBRILLEROSS, A
    TANG, SW
    COSCINA, DV
    PSYCHIATRY RESEARCH, 1982, 7 (02) : 145 - 151
  • [32] HUMAN BRAIN CORTEX AND PLATELET SEROTONIN-2 RECEPTOR-BINDING PROPERTIES AND THEIR REGULATION BY ENDOGENOUS SEROTONIN
    ANDRES, AH
    RAO, ML
    OSTROWITZKI, S
    ENTZIAN, W
    LIFE SCIENCES, 1993, 52 (03) : 313 - 321
  • [33] Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer's and Parkinson's Diseases
    Scharre, Douglas W.
    Chang, Shu-Ing
    Nagaraja, Haikady N.
    Park, Ariane
    Adeli, Anahita
    Agrawal, Punit
    Kloos, Anne
    Kegelmeyer, Deb
    Linder, Shannon
    Fritz, Nora
    Kostyk, Sandra K.
    Kataki, Maria
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (03) : 995 - 1004
  • [34] Cortical Sources of Resting State EEG Rhythms in Alzheimer's, Parkinson's, and Lewy Body Diseases
    Babiloni, Claudio
    INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 2021, 168 : S22 - S22
  • [35] Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease
    Benjamin, R
    Leake, A
    Ince, PG
    Perry, RH
    McKeith, IG
    Edwardson, JA
    Morris, CM
    NEURODEGENERATION, 1995, 4 (04): : 443 - 448
  • [36] THYMOSTHENIC EFFECTS OF RITANSERIN (R-55667), A CENTRALLY ACTING SEROTONIN-S2 RECEPTOR BLOCKER
    REYNTJENS, A
    GELDERS, YG
    HOPPENBROUWERS, MLJA
    VANDENBUSSCHE, G
    DRUG DEVELOPMENT RESEARCH, 1986, 8 (1-4) : 205 - 211
  • [37] EVIDENCE THAT PHOSPHOLIPID TURNOVER IS THE SIGNAL TRANSDUCING SYSTEM COUPLED TO SEROTONIN-S2 RECEPTOR-SITES
    DECOURCELLES, DD
    LEYSEN, JE
    DECLERCK, F
    VANBELLE, H
    JANSSEN, PAJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1985, 260 (12) : 7603 - 7608
  • [38] CHARACTERIZATION AND QUANTIFICATION OF SEROTONIN-S2 RECEPTOR-SITES ON HUMAN-BLOOD PLATELET MEMBRANES
    LEYSEN, JE
    GOMMEREN, W
    ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 1984, 272 (01): : 172 - 172
  • [39] SEROTONIN2 RECEPTOR-BINDING IN BLOOD-PLATELETS OF SCHIZOPHRENIC-PATIENTS
    ARORA, RC
    MELTZER, HY
    PSYCHIATRY RESEARCH, 1993, 47 (02) : 111 - 119
  • [40] REDUCTION IN SEROTONIN 5HT(2) RECEPTOR-BINDING ON PLATELETS OF DELINQUENT ADOLESCENTS
    BLUMENSOHN, R
    RATZONI, G
    WEIZMAN, A
    ISRAELI, M
    GREUNER, N
    APTER, A
    TYANO, S
    BIEGON, A
    PSYCHOPHARMACOLOGY, 1995, 118 (03) : 354 - 356